NASDAQ:MDGL Madrigal Pharmaceuticals Q3 2026 Earnings Report $499.59 +5.97 (+1.21%) As of 11:42 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Madrigal Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.84Beat/MissN/AOne Year Ago EPSN/AMadrigal Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$404.69 millionBeat/MissN/AYoY Revenue GrowthN/AMadrigal Pharmaceuticals Announcement DetailsQuarterQ3 2026Date11/3/2026TimeBefore Market OpensConference Call DateTuesday, November 3, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Madrigal Pharmaceuticals Earnings HeadlinesMadrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants3 hours ago | globenewswire.comBarclays Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)October 2, 2026 | theglobeandmail.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 6 at 1:00 AM | Banyan Hill Publishing (Ad)Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rated "Buy" in New Coverage at The Goldman Sachs GroupSeptember 27, 2026 | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Madrigal Pharmaceuticals (MDGL)September 25, 2026 | theglobeandmail.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 25, 2026 | americanbankingnews.comSee More Madrigal Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Madrigal Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your email. Email Address About Madrigal PharmaceuticalsMadrigal Pharmaceuticals (NASDAQ:MDGL) is a biopharmaceutical company focused on developing and commercializing therapies for chronic liver diseases. The company’s primary focus is metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease that can lead to significant liver fibrosis, cirrhosis and other complications. Madrigal’s lead product, Rezdiffra (resmetirom), is an oral thyroid hormone receptor beta agonist. In 2024, the U.S. Food and Drug Administration approved Rezdiffra for use with diet and exercise to treat adults with noncirrhotic MASH accompanied by moderate to advanced liver fibrosis. The therapy is designed to address liver fat and fibrosis associated with the disease. Headquartered in Conshohocken, Pennsylvania, Madrigal markets Rezdiffra in the United States and continues to pursue the development and potential international expansion of its liver disease portfolio. William Sibold serves as the company’s president and chief executive officer.View Madrigal Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AI Chip Demand Gives Linde a New Growth Catalyst3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street Divided Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
